🚀 VC round data is live in beta, check it out!
Aptahem Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aptahem and similar public comparables like Iterum Therapeutics, Nextgen Biomed, Biosenic, Reboost Blockchain and more.
Aptahem Overview
About Aptahem
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
Founded
2014
HQ
Employees
5
Website
Sectors
Financials (FY)
EV
$1M
Aptahem Financials
Aptahem reported last fiscal year revenue of — and negative EBITDA of ($683K).
In the same fiscal year, Aptahem generated $282K in gross profit, ($683K) in EBITDA losses, and had net loss of ($709K).
Aptahem P&L
In the most recent fiscal year, Aptahem reported revenue of — and EBITDA of ($683K).
Aptahem expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | $282K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($683K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($709K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aptahem Stock Performance
Aptahem has current market cap of $2M, and enterprise value of $1M.
Market Cap Evolution
Aptahem's stock price is $0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1M | $2M | 0.3% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAptahem Valuation Multiples
Aptahem trades at (1.7x) EV/EBITDA.
Aptahem Financial Valuation Multiples
As of April 19, 2026, Aptahem has market cap of $2M and EV of $1M.
Equity research analysts estimate Aptahem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aptahem has a P/E ratio of (2.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.1x | XXX | XXX | XXX |
| P/E | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aptahem Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aptahem Margins & Growth Rates
Aptahem's revenue in the last fiscal year grew by —.
Aptahem's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Aptahem Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (22%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aptahem Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aptahem | XXX | XXX | XXX | XXX | XXX | XXX |
| Iterum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nextgen Biomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosenic | XXX | XXX | XXX | XXX | XXX | XXX |
| Reboost Blockchain | XXX | XXX | XXX | XXX | XXX | XXX |
| Clearside Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aptahem M&A Activity
Aptahem acquired XXX companies to date.
Last acquisition by Aptahem was on XXXXXXXX, XXXXX. Aptahem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aptahem
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAptahem Investment Activity
Aptahem invested in XXX companies to date.
Aptahem made its latest investment on XXXXXXXX, XXXXX. Aptahem invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aptahem
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aptahem
| When was Aptahem founded? | Aptahem was founded in 2014. |
| Where is Aptahem headquartered? | Aptahem is headquartered in Sweden. |
| How many employees does Aptahem have? | As of today, Aptahem has over 5 employees. |
| Is Aptahem publicly listed? | Yes, Aptahem is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Aptahem? | Aptahem trades under APTA ticker. |
| When did Aptahem go public? | Aptahem went public in 2015. |
| Who are competitors of Aptahem? | Aptahem main competitors are Iterum Therapeutics, Nextgen Biomed, Biosenic, Reboost Blockchain. |
| What is the current market cap of Aptahem? | Aptahem's current market cap is $2M. |
| Is Aptahem profitable? | No, Aptahem is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.